Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL -1.64% Revenue per Share is A$0.01 as of Jun. 2026. The stock has 7 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Control Bionics ranks worse than 91.7% on this metric.
Control Bionics's revenue per share for the
six
months ended in Jun. 2026 was A$0.01.
Control Bionics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.01.
Warning Sign:
Control Bionics Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Control Bionics was -40.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -37.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -24.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Control Bionics's Revenue per Share or its related term are showing as below:
ASX:CBL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.4 Med: -21.8 Max: -17
Current: -37.4
During the past 7 years, Control Bionics's highest 3-Year average Revenue Per Share Growth Rate was -17.00% per year. The lowest was -37.40% per year. And the median was -21.80% per year.
ASX:CBL's 3-Year Revenue Growth Rate is ranked worse than 91.7% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 3.8
vs ASX:CBL: -37.40
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Control Bionics Revenue per Share Related Terms
Control Bionics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Control Bionics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, Control Bionics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Control Bionics's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Control Bionics's Revenue Per Share for the fiscal year that ended in Jun. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Revenue per Share of A$0.01 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #696 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 91.7%.
Is Control Bionics' Revenue per Share too high?
Control Bionics' current Revenue per Share is A$0.01. Based on the distribution chart, Control Bionics ranks #696 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #696 out of 759 companies for Revenue per Share. This places Control Bionics in the lower half of its industry. The industry median Revenue per Share is 3.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.80, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Revenue per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 200% above its estimated fair value. The current Revenue per Share is A$0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Revenue per Share is A$0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
